Related Experiment Video
Updated: Jun 4, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New oral anticoagulants.
Taki Galanis1, Lynda Thomson, Michael Palladino
1Jefferson Medical College, Thomas Jefferson University Hospitals, Jefferson Vascular Center, Suite 6270, Gibbon Building, 111 South 11th Street, Philadelphia, PA 19107, USA. Taki.Galanis@jefferson.edu
Journal of Thrombosis and Thrombolysis
|February 18, 2011
Summary
New oral anticoagulants like apixaban and rivaroxaban (Factor Xa inhibitors) and dabigatran (Factor IIa inhibitor) offer predictable anticoagulation. They simplify management of thromboembolic disorders without routine monitoring or significant interactions.
Area of Science:
- Pharmacology
- Clinical Medicine
- Thromboembolic Disorders
Background:
- New oral anticoagulants represent a significant advancement in clinical practice.
- Apixaban and rivaroxaban are Factor Xa inhibitors; dabigatran is a Factor IIa inhibitor.
- These agents offer a predictable pharmacological profile compared to traditional anticoagulants.
Purpose of the Study:
- To review the pharmacology of new oral anticoagulants.
- To examine clinical trials involving these agents in various indications.
- To highlight the potential of these drugs in managing thromboembolic disorders.
Main Methods:
- Review of pharmacological properties of new oral anticoagulants.
- Analysis of major clinical trials in specific patient populations.
- Evaluation of drug interactions and food effects.
Main Results:
- New oral anticoagulants demonstrate predictable pharmacokinetics.
- Routine coagulation monitoring is not required.
- Minimal food and drug-drug interactions observed due to limited CYP450 metabolism.
Conclusions:
- New oral anticoagulants offer a simplified approach to anticoagulation therapy.
- These agents are effective in venous thromboembolism prevention, treatment, and stroke prevention in atrial fibrillation.
- The unique profile of these drugs may revolutionize the management of thromboembolic disorders.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:23Oral Drug Delivery Systems: Introduction
Oral drug delivery is the most common route of administration due to its convenience, cost-effectiveness, and high patient compliance. It enables precise formulation to ensure proper drug dosage and bioavailability. The development of oral dosage forms considers drug properties such as solubility, stability, and absorption to optimize therapeutic efficacy.Tablets, capsules, liquids, and chewable formulations enhance drug stability, mask undesirable tastes, and improve patient experience.
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...